Efficacy of the latanoprost versus timolol/dorzolamide combination therapy in patients with primary open angle glaucoma

OBJECTIVE: Efficacy of the latanoprost versus timolol/dorzolamide combination therapy in patients with primary open angle glaucoma

METHODS: The study was designed as a 6 months randomized, observer-masked study comprising 120 patients with primary open-angle glaucoma in Feiz Hospital, Isfahan, Iran, from 2006 to 2007. The patients were randomized latanoprost, n = 60; dorzolamide/timolol, n = 60 to treatment with either latanoprost, 0.005% once daily, or the combination of timolol 0.5% twice daily, and dorzolamide 2% 3 times daily. The mean intraocular pressure IOP after one, 3, and 6 months of treatment was compared with baseline in the 2 groups

RESULTS: A total of 120 patients were randomized to 2 equal treatment groups. The mean baseline IOP values were similar between the 2 groups. The mean standard error of mean [SE] IOP reductions at months one was 7.2 0.4, at month 3 was 7.3 0.4, and at month 6 was 7.1 0.3 mm Hg for the latanoprost group and 7.5 0.3, 7.8 0.3, and 7.4 0.3 mm Hg for the dorzolamide/timolol group. The 2 therapies were similarly effective

CONCLUSION: The latanoprost and dorzolamide/timolol combination were equally effective at lowering IOP compared to untreated baseline.